Skip to main content

Table 2 Treatment-emergent adverse events (TEAEs) reported in ≥5% patients by organ system

From: Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

System Organ Class Samalizumab Treatment Group
50 mg/m2 N = 4 100 mg/m2 N = 5 200 mg/m2 N = 3 300 mg/m  N = 3 400 mg/m2 N = 3 500 mg/m2 N = 7 600 mg/m2 N = 1 Overall N = 26
General Disorders and Administration Sites         11 (42)
 Fatigue 1 (25) 1 (33) 3 (100) 1 (14)  
 Peripheral coldness 1 (25)  
 Pyrexia 1 (14)  
 Chills 1 (14)  
 Edema 2 (67)  
Skin and Subcutaneous Tissue         9 (35)
 Erythema 1 (33)  
 Night sweats 1 (14)  
 Pruritus 1 (25) 1 (20)  
 Rash 1 (25) 1 (20) 1 (33) 1 (33)  
 Urticaria 1 (25)  
Gastrointestinal         5 (19)
 Abdominal distension 1 (33)  
 Abdominal Pain 2 (67)  
 Diarrhea 1 (25) 1 (20)  
Infections and Infestations         4 (15)
 Upper Respiratory Tract Infection 1 (20) 1 (33) 1 (14)  
 Abscess 1 (33)  
Musculoskeletal and Connective Tissue         4 (15)
 Arthralgia 1 (33)  
 Muscular weakness 1 (25)  
 Myalgia 1 (25)  
 Stiffness 1 (20)  
Nervous System         3 (12)
 Dizziness 1 (33)  
 Headache 1 (14)  
 Paraesthesia 1 (33)  
Blood and Lymphatic System         7 (27)
 Anemia 1 (33) 1 (33)  
 Neutropenia 2 (50) 1 (33) 1 (33)  
 Thrombocytopenia 1 (33)  
Eye         6 (23)
 Eye pain 1 (25) 1 (14)  
 Night blindness 1 (25)  
 Photophobia 1 (25) 1 (14)  
 Reduced visual acuity 1 (25)  
Laboratory    2 (8)
 Increased blood viscosity    1 (33)    
 Decreased platelets   1 (20)      
Respiratory, Thoracic and Mediastinal         4 (15)
 Cough 1 (14)  
 Dyspnea 1 (33) 1 (14)  
 Pulmonary edema 1 (14)  
  1. Values in parentheses are the percentage of patients
  2. Only one occurrence per patient counted for each category
  3. “-” indicates zero